MediciNova, Inc. (MNOV)
1.46
+0.01
(+0.69%)
USD |
NASDAQ |
Nov 06, 16:00
1.45
-0.01
(-0.68%)
After-Hours: 20:00
MediciNova Enterprise Value : 46.56M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 46.56M |
| November 05, 2026 | 46.07M |
| November 04, 2026 | 46.07M |
| November 03, 2026 | 44.60M |
| November 02, 2026 | 45.58M |
| October 30, 2026 | 43.61M |
| October 29, 2026 | 43.61M |
| October 28, 2026 | 47.06M |
| October 27, 2026 | 44.10M |
| October 26, 2026 | 43.61M |
| October 23, 2026 | 43.12M |
| October 22, 2026 | 44.10M |
| October 21, 2026 | 44.10M |
| October 20, 2026 | 41.64M |
| October 19, 2026 | 43.61M |
| October 16, 2026 | 44.60M |
| October 15, 2026 | 46.07M |
| October 14, 2026 | 47.06M |
| October 13, 2026 | 48.53M |
| October 12, 2026 | 50.50M |
| October 09, 2026 | 49.52M |
| October 08, 2026 | 50.50M |
| October 07, 2026 | 53.95M |
| October 06, 2026 | 55.92M |
| October 05, 2026 | 61.08M |
| Date | Value |
|---|---|
| October 02, 2026 | 62.31M |
| October 01, 2026 | 54.93M |
| September 30, 2026 | 57.15M |
| September 29, 2026 | 69.21M |
| September 28, 2026 | 78.07M |
| September 25, 2026 | 101.69M |
| September 24, 2026 | 105.14M |
| September 23, 2026 | 112.52M |
| September 22, 2026 | 117.44M |
| September 21, 2026 | 137.13M |
| September 18, 2026 | 138.12M |
| September 17, 2026 | 144.51M |
| September 16, 2026 | 98.74M |
| September 15, 2026 | 74.13M |
| September 14, 2026 | 66.74M |
| September 11, 2026 | 63.79M |
| September 10, 2026 | 60.35M |
| September 09, 2026 | 62.81M |
| September 08, 2026 | 60.84M |
| September 04, 2026 | 54.93M |
| September 03, 2026 | 54.44M |
| September 02, 2026 | 45.09M |
| September 01, 2026 | 45.58M |
| August 31, 2026 | 45.33M |
| August 28, 2026 | 45.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 976.60M |
| Viking Therapeutics, Inc. | 2.718B |
| IDEAYA Biosciences, Inc. | 2.211B |
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.314M |
| Revenue (Quarterly) | 0.4584M |
| Total Expenses (Quarterly) | 2.773M |
| EPS Diluted (Quarterly) | -0.047 |
| Gross Profit Margin (Quarterly) | 68.22% |
| Profit Margin (Quarterly) | -504.8% |
| Earnings Yield | -14.98% |
| Normalized Earnings Yield | -14.99 |